CMOs are exploring the potential of mammalian cell culture production amidst soaring demand for biopharmaceutical contract manufacturing services. Incumbents, such as Charles River and Lonza have furthered investments in mammalian cells. To illustrate, in May 2021, Lonza announced pouring USD 936 million to bolster the footprint of mammalian drug substance manufacturing sites in the U.S. and Switzerland.

Biopharmaceutical firms are responding to the demand for outsourced services with bullish investments in research activities. For instance, in July 2022, Wuxi Biologics contemplated expanding its large-scale drug product & drug substance manufacturing capabilities and R&D in Singapore.

Get your copy or request a free sample of the report @ https://www.grandviewresearch.com/market-trends/biopharmaceutical-cmo-cro-production-capacity-study